Morten Kranker Larsen

Dr. Morten Kranker Larsen


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
MLMorten Kranker Larsen
Morten Kranker Larsen
VSVibe Skov
Vibe Skov
LKLasse Kjær
Lasse Kjær
CEChristina Schjellerup Eickhardt-Dalbøge
Christina Schjellerup Eickhardt-Dalbøge
TKTrine Alma Knudsen
Trine Alma Knudsen
CEChristina Ellervik
Christina Ellervik
The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1–1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03–2.09) for the whole population and 2.93(2.44–3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71–2.69), 2.19(1.89–2.54), and 2.31(1.91–2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10–16), with a HR for NLR ≥ 6 of 2.23(2.17–2.29), 4.10(4.01–4.20), and 7.69(7.50–7.89), for CCI-score 0, 1–2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.

14 October 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KPKasper M. Pedersen
Kasper M. Pedersen
MBMarie Bak
Marie Bak
ASAnders L. Sørensen
Anders L. Sørensen
AZAnn‐Dorthe Zwisler
Ann‐Dorthe Zwisler
CEChristina Ellervik
Christina Ellervik
JTJanne S Tolstrup
Janne S Tolstrup
Background: Former studies on smoking as a risk factor for Philadelphia‐negative myeloproliferative neoplasms (MPNs) have mainly been carried out in women's cohorts and studies with various definitions of MPNs. Herein, we conducted a cohort study with register‐based follow‐up of a general population from Denmark, to validate and substantiate prior observations.Methods: In the Danish Health Examination Survey cohort, we used the Cox proportional‐hazards model adjusted for age, sex, body mass index, and level of education, to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/ex‐smokers had an increased risk of MPNs compared to never‐smokers.Results: From the time of data collection (September 2007 to October 2008) until 1 January 2015, 70 individuals were diagnosed with MPNs among 75 896 study participants. Similar results were observed in both the age and sex adjusted analysis and the multivariable analysis. The multivariable HR of any MPN diagnosis for daily smokers was 2.5 (95% CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95% CI: 0.5‐5.8), 1.7 (95% CI: 0.5‐5.8), 4.3 (95% CI: 0.9‐19), and 6.2 (95% CI: 1.5‐25), respectively. Among occasional/ex‐smokers the corresponding HRs were 1.9 (95% CI: 1.1‐3.3), 1.5 (95% CI: 0.6‐3.7), 0.8 (95% CI: 0.3‐2.4), 0.9 (95% CI: 0.2‐4.4), and 6.2 (95% CI: 1.8‐21). Participants, who smoked >15 g/day, had an overall HR of 3.4 (95% CI: 1.4‐8.2) for any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 2.1 (95% CI: 0.9‐4.7).Conclusion: Smoking was associated with MPN development when comparing smokers and never‐smokers. Further studies investigating smoking in MPNs are warranted to substantiate our findings.

29 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
MKMarie Hvelplund Kristiansen
Marie Hvelplund Kristiansen
LKLasse Kjaer
Lasse Kjaer
VSVibe Skov
Vibe Skov
MLMorten Kranker Larsen
Morten Kranker Larsen
CEChristina Ellervik
Christina Ellervik
TWTroels Wienecke
Troels Wienecke
Ischemic stroke has a high recurrence rate despite treatment. This underlines the significance of investigating new possible cerebrovascular risk factors, such as the acquired gene mutation JAK2V617F found in 3.1% of the general population. We aimed to investigate the prevalence of the JAK2V617F mutation in a population with ischemic stroke compared with that in matched controls. We enrolled 538 consecutive Danish patients with ischemic stroke (mean age, 69.5 ± 10.9 years; 39.2% female) within 7 days of symptom onset. Using multiple-adjusted conditional logistic regression analysis, we compared the prevalence of JAK2V617F with that in age- and sex-matched controls free of ischemic cerebrovascular disease (ICVD) from the Danish General Suburban Population Study. DNA was analyzed for JAK2V617F mutation using sensitive droplet digital polymerase chain reaction in patients and controls. Of the 538 patients with ischemic stroke, 61 (11.3%) had JAK2V617F mutation. There were no differences in patient demographics or cerebrovascular comorbidities between the patients with and without mutations. Patients with ischemic stroke were more likely to have the JAK2V617F mutation than matched controls, in whom the JAK2V617F prevalence was 4.4% (odds ratio, 2.37; 95% confidence interval, 1.57-3.58; P < .001). A subanalysis stratified by smoking history revealed that the association was strongest in current smokers (odds ratio, 4.78; 95% confidence interval, 2.22-10.28; P < .001). Patients with ischemic stroke were 2.4 times more likely to have the JAK2V617F mutation than matched controls without ICVD when adjusting for other cerebrovascular risk factors. This finding supports JAK2V617F mutation as a novel cerebrovascular risk factor.

14 March 2018 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
HBH. K. M. Bergholdt
H. K. M. Bergholdt
MLMorten Kranker Larsen
Morten Kranker Larsen
AVA. Varbo
A. Varbo
BNB. G. Nordestgaard
B. G. Nordestgaard
CEChristina Ellervik
Christina Ellervik
Background: Whether a causal relationship exists between milk intake and reduced risk of fractures is unclear.Objectives: We tested the hypothesis that genetically determined milk intake reduces the risk of fractures and increases bone mineral density (BMD).Methods: We investigated the association between milk intake, LCT‐13910 C/T (rs4988235), which is associated with lactase persistence (TT/TC) in Northern Europeans, and hip fractures in three Danish prospective studies (N = 97 811, age ≥20 years). We added meta‐analyses of LCT‐13910 and fractures and BMD from five published Northern European population studies.Results: In the Danish studies, the adjusted hazard ratio (HR) for hip fracture per one glass per week higher milk intake was 1.00 (95% CI: 0.99–1.01). The per T‐allele milk intake was 0.58 (0.49–0.68) glasses per week, but HR was 1.01 (0.94–1.09) for hip fracture. In meta‐analyses of Danish studies with published Northern European population studies, the random effects odds ratio for any fracture was 0.86 (0.61–1.21; I2 = 73%) for TT vs. CC and 0.90 (0.68–1.21; I2 = 63%) for TC vs. CC. The standardized mean difference in femoral neck BMD was 0.10 (0.02–0.18; I2 = 0%) g cm−2 for TT vs. CC and 0.06 (−0.04 to 0.17; I2 = 17%) g cm−2 for TC vs. CC. There were no differences in lumbar spine or total hip BMD comparing TT or TC with CC.Conclusion: Genetically lifelong lactase persistence with high milk intake was not associated with hip fracture in Danish population‐based cohorts. A meta‐analysis combining Danish studies with published Northern European population studies also showed that lactase persistence was not associated with fracture risk. Genetic lactase persistence was associated with a higher femoral neck BMD, but not lumbar spine or total hip BMD.

25 December 2019 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NJNimesh A. Jayasuriya
Nimesh A. Jayasuriya
AKAlisa Kjaergaard
Alisa Kjaergaard
KPKasper M. Pedersen
Kasper M. Pedersen
ASAnders L. Sørensen
Anders L. Sørensen
MBMarie Bak
Marie Bak
CEChristina Ellervik
Christina Ellervik

21 August 2022 in European Journal of Haematology
Verified
Journal Article
Open access
MLMorten Kranker Larsen
Morten Kranker Larsen
VSVibe Skov
Vibe Skov
LKLasse Kjaer
Lasse Kjaer
NMNatascha A. Møller‐Palacino
Natascha A. Møller‐Palacino
RPRasmus K. Pedersen
Rasmus K. Pedersen
CEChristina Ellervik
Christina Ellervik
The myeloproliferative neoplasms are associated with chronic kidney disease but whether clonal haematopoiesis of indeterminate potential (CHIP) is associated with impaired kidney function is unknown. In the Danish General Suburban Population Study (N = 19 958) from 2010 to 2013, 645 individuals were positive for JAK2V617F (N = 613) or CALR (N = 32) mutations. Mutation‐positive individuals without haematological malignancy were defined as having CHIP (N = 629). We used multiple and inverse probability weighted (IPW)‐adjusted linear regression analysis to estimate adjusted mean (95% confidence interval) differences in estimated glomerular filtration rate (eGFR; ml/min/1.73 m2) by mutation status, variant allele frequency (VAF%), blood cell counts, and neutrophil‐to‐lymphocyte ratio (NLR). We performed 11‐year longitudinal follow‐up of eGFR in all individuals. Compared to CHIP‐negative individuals, the mean differences in eGFR were −5.6 (−10.3, −0.8, p = .02) for CALR, −11.9 (−21.4, −2.4, p = 0.01) for CALR type 2, and −10.1 (−18.1, −2.2, p = .01) for CALR with VAF ≥ 1%. The IPW‐adjusted linear regression analyses showed similar results. NLR was negatively associated with eGFR. Individuals with CALR type 2 had a worse 11‐year longitudinal follow‐up on eGFR compared to CHIP‐negative individuals (p = .004). In conclusion, individuals with CALR mutations, especially CALR type 2, had impaired kidney function compared to CHIP‐negative individuals as measured by a lower eGFR at baseline and during 11‐year follow‐up.